About Xilis
Developing next generation ex-vivo technology to accelerate and de-risk drug development from discovery to clinical trial, and to guide precision cancer therapy.
Headquarters
Durham, North CarolinaWebsite
https://www.xilis.comCompany Size
51-200 employeesIndustry
BiotechnologyCompany Type
Privately HeldFounded
2026Specialties
organoids, precision medicine, oncology, cancer, tissue engineering, microfluidics, ex vivo, screening, machine learning, and artificial intelligence